Male Reproductive Cancers Archives - Page 2 of 69

Genitourinary Cancers Symposium 2019

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

By

Jody A. Charnow

February 14, 2019

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.

Novel targeted and immunological therapies may help improve the outlook for patients with renal cell

Prostate Cancer

Radium-223 Combination Found Not Beneficial For Certain Patients With Castration-Resistant Prostate Cancer

By

Susan Moench, PhD, PA-C

February 13, 2019

Patients with metastatic CRPC and bone metastases treated with abiraterone plus prednisone/prednisolone had a higher risk of bone fractures when receiving concomitant radium-223.

Active surveillance provides an important alternative to immediate treatment for early-stage, low-ri

Prostate Cancer

Prostate Cancer Active Surveillance Increasing in the US

By

Natasha Persaud

February 12, 2019

From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.

Researchers also used the trial to collect more information on safety, patient-reported outcomes, an

Prostate Cancer

Current Guidelines for Germline Genetic Testing in Prostate Cancer May Be Insufficient

By

Susan Moench, PhD, PA-C

February 7, 2019

A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.

Almac Diagnostics has published analytical validation of a 70-gene assay designed for use with forma

Prostate Cancer

Gene-Expression Assay for Metastatic Prostate Cancer Put to the Test

By

Caroline Seydel

January 28, 2019

Almac Diagnostics has published analytical validation of a 70-gene assay designed for use with formalin-fixed paraffin-embedded samples.

Bipolar androgen therapy may benefit some men with asymptomatic CRPC who have a low to moderate meta

Prostate Cancer

MSI-H/dMMR Is Clinically Meaningful, Despite Being Uncommon in Prostate Cancer

By

Christina Bennett, MS

January 9, 2019

Biomarkers of PD-1/PD-L1 checkpoint inhibitor response in prostate cancer could help stratify patients by response.

Prostate Cancer

Overactive Bladder Linked to Prostate Cancer ADT

By

Jody A. Charnow

January 8, 2019

Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.

Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen

Prostate Cancer

Prostate Cancer Possibly Linked to Zinc Intake

By

Jody A. Charnow

January 8, 2019

In a Spanish study, the highest vs lowest tertile of dietary zinc intake was associated with a significant 66% increased relative risk of low-grade prostate cancer.

Statin use in patients with kidney cancer improved cancer-specific survival and overall survival.

Prostate Cancer

Statins Plus ADT May Up Survival in Advanced Prostate Cancer

By

Jody A. Charnow

December 27, 2018

Statin use by men receiving androgen deprivation therapy for advanced PCa was associated with decreased risk of overall and cancer-specific mortality.

While a recent discovery of a series of communicable cancers has raised concerns, there has been no

Prostate Cancer

Hypofractionated Radiotherapy May Benefit Patients With Localized Prostate Cancer

By

John Schieszer, MA

December 19, 2018

A study suggests HIMRT may have some advantages over CIMRT for treating men with localized prostate cancer.